Skip to content
Screener

Bicara Therapeutics BCAX Return on equity

Return on equity at other companies

Eli Lilly logo
Eli LillyLLY
102.4%+15.7pp
Amgen logo
AmgenAMGN
91.5%-7.7pp
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-55.2%+8.0pp
Arcus Biosciences logo
Arcus BiosciencesRCUS
-90.8%+373pp
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-197.8%-2,158pp
Immunome logo
ImmunomeIMNM
-50.1%-10.8pp

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K—
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.81B+217%
Enterprise value$1.49B+1,000%

Returns & leverage

See full
Debt / equity0×0.0×
Current ratio13.9×-10.8×

Where this comes from

Calculated from Bicara Therapeutics’s reported figures.

net income/total stockholders equity=-32.3%

Based on trailing twelve months.

The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026. Open the filing →

Filed
May 11, 2026, 4:03 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-033429

FAQ

What is Bicara Therapeutics's return on equity?
Bicara Therapeutics (BCAX) reported return on equity of -32.3% in Q1 2026.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.

Ask your AI about Bicara Therapeutics's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude